Discussion
PD, primary TNBC, TRAEs
The results from the NEOTALA study showed that talazoparib monotherapy was active, despite not meeting the predefined threshold, and was well tolerated in the neoadjuvant setting. The pCR rate by ICR was 45.8% (95% CI, 32.0%-60.6%) and 49.2% (95% CI, 36.7%-61.6%) in the evaluable and ITT analysis population, respectively, and comparable with pCR rates previously observed with neoadjuvant ­chemotherapy regimens with combination anthracycline- and taxane-based chemotherapy regimens.In this study, 10 (16.4%) patients experienced PD with ­talazoparib, which may reflect PARP inhibitor resistance in these patients. In the phase II PETREMAC study, which evaluated neoadjuvant olaparib monotherapy, no patients with primary TNBC and TRAEs were consistent with the established safety profile of talazoparibNEOTALA was limited by its non-randomized, single-arm design, small sample size, and early termination due to sponsor decision. In addition, response assessment per breast ultrasound scan was non-standardized so could not be determined.Other clinical studies have demonstrated the utility of PARP inhibitors in this patient population. The phase III OlympiA study assessed olaparib in patients with high-risk HER2-negative germline Multiple ongoing neoadjuvant studies may further clarify the optimal use of PARP inhibitors in germline 